Humacyte (HUMA) Projected to Post Earnings on Friday

Humacyte (NASDAQ:HUMA - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Friday, May 9th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $0.46 million for the quarter.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.07. The firm had revenue of $7.23 million during the quarter, compared to analyst estimates of $0.64 million. On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Price Performance

Humacyte stock traded down $0.01 during trading on Wednesday, reaching $1.22. 1,406,157 shares of the company were exchanged, compared to its average volume of 3,632,681. Humacyte has a 52-week low of $1.15 and a 52-week high of $9.97. The stock's 50 day simple moving average is $2.03 and its two-hundred day simple moving average is $3.68. The company has a market capitalization of $189.25 million, a P/E ratio of -0.91 and a beta of 1.64.

Insider Activity at Humacyte

In other news, Director Kathleen Sebelius acquired 50,000 shares of the company's stock in a transaction that occurred on Tuesday, April 8th. The shares were purchased at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the acquisition, the director now owns 91,207 shares of the company's stock, valued at approximately $120,393.24. This represents a 121.34 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Dale A. Sander bought 20,000 shares of the company's stock in a transaction that occurred on Thursday, April 10th. The stock was purchased at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the acquisition, the chief financial officer now directly owns 40,600 shares in the company, valued at approximately $62,118. This trade represents a 97.09 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 83,993 shares of company stock worth $118,224 in the last three months. 11.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

HUMA has been the topic of several research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Humacyte in a report on Wednesday, March 12th. Benchmark reiterated a "buy" rating on shares of Humacyte in a report on Thursday, February 27th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of Humacyte in a report on Wednesday, March 26th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Humacyte currently has a consensus rating of "Buy" and a consensus price target of $13.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.